Exploiting epigenetic vulnerabilities for cancer therapeutics

B Mair, S Kubicek, SMB Nijman - Trends in pharmacological sciences, 2014 - cell.com
Epigenetic deregulation is a hallmark of cancer, and there has been increasing interest in
therapeutics that target chromatin-modifying enzymes and other epigenetic regulators. The …
被引用次数：75 相关文章

Exploiting epigenetic vulnerabilities for cancer therapeutics.

B Mair, S Kubicek, S Nijman - Trends in pharmacological sciences, 2014 - ora.ox.ac.uk
Epigenetic deregulation is a hallmark of cancer, and there has been increasing interest in
therapeutics that target chromatin-modifying enzymes and other epigenetic regulators. The …

Exploiting epigenetic vulnerabilities for cancer therapeutics

B Mair, S Kubicek, SMB Nijman - Trends in Pharmacological Sciences, 2014 - cell.com
Epigenetic deregulation is a hallmark of cancer, and there has been increasing interest in
therapeutics that target chromatin-modifying enzymes and other epigenetic regulators. The …

Exploiting epigenetic vulnerabilities for cancer therapeutics

B Mair, S Kubicek, SMB Nijman - Trends in Pharmacological Sciences, 2014 - Elsevier
Highlights•Epigenetic deregulation as a cancer vulnerability concept is discussed.•A more
general consideration of chromatin regulators as anticancer therapeutic targets is …

Exploiting epigenetic vulnerabilities for cancer therapeutics

B Mair, S Kubicek, SMB Nijman - Trends in …, 2014 - pubmed.ncbi.nlm.nih.gov
Epigenetic deregulation is a hallmark of cancer, and there has been increasing interest in
therapeutics that target chromatin-modifying enzymes and other epigenetic regulators. The …

Exploiting epigenetic vulnerabilities for cancer therapeutics.

B Mair, S Kubicek, SM Nijman - Trends in Pharmacological …, 2014 - europepmc.org
Epigenetic deregulation is a hallmark of cancer, and there has been increasing interest in
therapeutics that target chromatin-modifying enzymes and other epigenetic regulators. The …